[Experience of immunotherapy with leukinferon in the comprehensive therapy of breast cancer].
Patients with breast tumors, stage IIb-IIIb, received complex treatment including radiation therapy, radical surgery and polychemotherapy. Some of them were also injected 4-40 doses of leukinferon, im, for immunocorrection. The latter treatment carried out during radiotherapy and preparation for surgery prevented lymphopenia development. Leukinferon administered during 6-8 courses of cytostatic polychemotherapy was followed by a significant rise in lymphocyte concentration. Leukinferon-treated patients, on the whole, revealed higher rates of postoperative rehabilitation, improved tolerance of rigorous treatment and lower frequency of metastatic development. A correlation was established between preoperative lymphocyte level and risk of metastasis development at later stages. No metastasis or recurrence was detected within 15-42 months in 16 patients who received leukinferon throughout the entire period of treatment.
Korobkova
L I
LI
Kuznetsov
V P
VP
Rasskazchikova
E S
ES
Beliaev
D L
DL
Vel'sher
L Z
LZ
Babadiants
A A
AA
Zverev
M P
MP
Strekalovskiĭ
S V
SV
Zueva
L A
LA
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D016207:Cytokines / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008875:Middle Aged; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D016207:Cytokines; D004338:Drug Combinations; D007370:Interferon Type I; C062252:leukinferon